THIS UNKNOWN GEM IS DEFINITELY THE CHEAPEST STOCK IN THE BIOTECH SECTOR .PLEASE DO YOUR OWN DD AND REALIZE THE MEGA MONSTER POTENTIAL GLTA
Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by mid 2013 because of its very low burn-rate of $1.2 Mil a year !
2x New NDA filings for Migraine and Erectile Dysfunction indication in early 2013 . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years (see pipeline chart below) !
IGXT has NO DEBT and current Market cap of only $29 M is really a BIG BIG BARGAIN .
My Target is $8-12 within 2 Years .GLTA
Market Cap : $ 29 M
Cash: $ 3 M ( Burn-rate only $1.2 M a year )
Price : 0.59 $
Shares Out : 50 M ( 26 M shares are held by Insiders + Institutions)
Fantastic Prodcut Pipeline
Latest Presentation Oct 2012
Big Buying by Institutions
IGXT gets 18 month $3.00 Price Target from AEGIS CAPITAL CORP on October 5th, 2012
The Event- Forfivo XL is now officially launched in the US
IntelGenx striving to create a second Biovail
IntelGenx to file anti-migraine NDA in first 2013
IntelGenx’s anti-migraine VersaFilm is undergoing a pivotal stability study, with a 505(b)(2) new drug application expected to be filed with the FDA in the first quarter of 2013, the company says in its second quarter report.
In May, IntelGenx announced positive pivotal study results for the anti-migraine product, demonstrating that it is bioequivalent to Merck’s orally disintegrating tablet Maxalt-MLT. Sales of Maxalt-MLT grew 16% to $639-million in 2011.
IntelGenx developed the anti-migraine product under a co-development and commercialization agreement with RedHill Biopharma of Israel. In addition to milestone payments, Intelgenx is entitled to receive a share of all proceeds including, but not limited to, all sales milestones and income from the product world-wide.
“We were very busy throughout the second quarter with supporting the manufacturing activities and preparation of launch activities for Forfivo XL, which we anticipate will occur later in the third quarter,” CEO Dr. Horst Zerbe said in the quarterly report.
In addition to launch and sales milestones in the U.S. from marketing partner Edgemont Pharmaceuticals, IntelGenx will receive double-digit royalties on the net sales of Forfivo XL.
Forfivo XL is a novel, high strength formulation of bupropion HCl, the active ingredient in Wellbutrin XL. When launched, Forfivo will provide high-dose bupropion XL patients with the opportunity to achieve their entire daily dose in a single pill versus the multiple pills they currently need to take.
Reducing the number of tablets per dose significantly increases patient compliance and reduces the chance of an accidental overdose. These two factors are recognized as well-published and important clinical benefits, IntelGenx noted.